Research ExplorerPublicationsThe impact of pre-transplantation diabetes and obesity on ac...

The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party

Standard

The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party. / Gjærde, Lars Klingen; Ruutu, Tapani; Peczynski, Christophe; Boreland, William; Kröger, Nicolaus; Blaise, Didier; Schroeder, Thomas; Peffault de Latour, Régis; Gedde-Dahl, Tobias; Kulagin, Aleksandr; Sengeløv, Henrik; Yakoub-Agha, Ibrahim; Finke, Jürgen; Eder, Matthias; Basak, Grzegorz; Moiseev, Ivan; Schoemans, Hélène; Koenecke, Christian; Penack, Olaf; Perić, Zinaida.

In: BONE MARROW TRANSPL, Vol. 59, No. 2, 02.2024, p. 255-263.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gjærde, LK, Ruutu, T, Peczynski, C, Boreland, W, Kröger, N, Blaise, D, Schroeder, T, Peffault de Latour, R, Gedde-Dahl, T, Kulagin, A, Sengeløv, H, Yakoub-Agha, I, Finke, J, Eder, M, Basak, G, Moiseev, I, Schoemans, H, Koenecke, C, Penack, O & Perić, Z 2024, 'The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party', BONE MARROW TRANSPL, vol. 59, no. 2, pp. 255-263. https://doi.org/10.1038/s41409-023-02154-6

APA

Gjærde, L. K., Ruutu, T., Peczynski, C., Boreland, W., Kröger, N., Blaise, D., Schroeder, T., Peffault de Latour, R., Gedde-Dahl, T., Kulagin, A., Sengeløv, H., Yakoub-Agha, I., Finke, J., Eder, M., Basak, G., Moiseev, I., Schoemans, H., Koenecke, C., Penack, O., & Perić, Z. (2024). The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party. BONE MARROW TRANSPL, 59(2), 255-263. https://doi.org/10.1038/s41409-023-02154-6

Vancouver

Gjærde LK, Ruutu T, Peczynski C, Boreland W, Kröger N, Blaise D et al. The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party. BONE MARROW TRANSPL. 2024 Feb;59(2):255-263. https://doi.org/10.1038/s41409-023-02154-6

Bibtex

@article{6d38036f4a6244a8a9692dbde55ce389,
title = "The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party",
abstract = "Obesity and diabetes can modulate immune responses, which may impact allogeneic HCT outcomes and GvHD. From the EBMT registry, we included 36,539 adult patients who underwent allogeneic HCT for a hematological malignancy between 2016 and 2020. Of these, 5228 (14%) had obesity (BMI ≥ 30 kg/m2), 1415 (4%) had diabetes (requiring treatment with insulin or oral hypoglycemics), and 688 (2%) had obesity + diabetes pre-transplantation. Compared with patients without diabetes or obesity, the hazard ratio (HR) of grade II-IV acute GvHD was 1.00 (95% confidence interval [CI] 0.94-1.06, p = 0.89) for patients with obesity, 0.95 (CI 0.85-1.07, p = 0.43) for patients with diabetes, and 0.96 (CI 0.82-1.13, p = 0.63) for patients with obesity + diabetes. Non-relapse mortality was higher in patients with obesity (HR 1.08, CI 1.00-1.17, p = 0.047), diabetes (HR 1.40, CI 1.24-1.57, p < 0.001), and obesity + diabetes (HR 1.38, CI 1.16-1.64, p < 0.001). Overall survival after grade II-IV acute GvHD was lower in patients with diabetes (HR 1.46, CI 1.25-1.70, p < 0.001). Pre-transplantation diabetes and obesity did not influence the risk of developing acute GvHD, but pre-transplantation diabetes was associated with poorer survival after acute GvHD.",
author = "Gj{\ae}rde, {Lars Klingen} and Tapani Ruutu and Christophe Peczynski and William Boreland and Nicolaus Kr{\"o}ger and Didier Blaise and Thomas Schroeder and {Peffault de Latour}, R{\'e}gis and Tobias Gedde-Dahl and Aleksandr Kulagin and Henrik Sengel{\o}v and Ibrahim Yakoub-Agha and J{\"u}rgen Finke and Matthias Eder and Grzegorz Basak and Ivan Moiseev and H{\'e}l{\`e}ne Schoemans and Christian Koenecke and Olaf Penack and Zinaida Peri{\'c}",
note = "{\textcopyright} 2023. The Author(s).",
year = "2024",
month = feb,
doi = "10.1038/s41409-023-02154-6",
language = "English",
volume = "59",
pages = "255--263",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party

AU - Gjærde, Lars Klingen

AU - Ruutu, Tapani

AU - Peczynski, Christophe

AU - Boreland, William

AU - Kröger, Nicolaus

AU - Blaise, Didier

AU - Schroeder, Thomas

AU - Peffault de Latour, Régis

AU - Gedde-Dahl, Tobias

AU - Kulagin, Aleksandr

AU - Sengeløv, Henrik

AU - Yakoub-Agha, Ibrahim

AU - Finke, Jürgen

AU - Eder, Matthias

AU - Basak, Grzegorz

AU - Moiseev, Ivan

AU - Schoemans, Hélène

AU - Koenecke, Christian

AU - Penack, Olaf

AU - Perić, Zinaida

N1 - © 2023. The Author(s).

PY - 2024/2

Y1 - 2024/2

N2 - Obesity and diabetes can modulate immune responses, which may impact allogeneic HCT outcomes and GvHD. From the EBMT registry, we included 36,539 adult patients who underwent allogeneic HCT for a hematological malignancy between 2016 and 2020. Of these, 5228 (14%) had obesity (BMI ≥ 30 kg/m2), 1415 (4%) had diabetes (requiring treatment with insulin or oral hypoglycemics), and 688 (2%) had obesity + diabetes pre-transplantation. Compared with patients without diabetes or obesity, the hazard ratio (HR) of grade II-IV acute GvHD was 1.00 (95% confidence interval [CI] 0.94-1.06, p = 0.89) for patients with obesity, 0.95 (CI 0.85-1.07, p = 0.43) for patients with diabetes, and 0.96 (CI 0.82-1.13, p = 0.63) for patients with obesity + diabetes. Non-relapse mortality was higher in patients with obesity (HR 1.08, CI 1.00-1.17, p = 0.047), diabetes (HR 1.40, CI 1.24-1.57, p < 0.001), and obesity + diabetes (HR 1.38, CI 1.16-1.64, p < 0.001). Overall survival after grade II-IV acute GvHD was lower in patients with diabetes (HR 1.46, CI 1.25-1.70, p < 0.001). Pre-transplantation diabetes and obesity did not influence the risk of developing acute GvHD, but pre-transplantation diabetes was associated with poorer survival after acute GvHD.

AB - Obesity and diabetes can modulate immune responses, which may impact allogeneic HCT outcomes and GvHD. From the EBMT registry, we included 36,539 adult patients who underwent allogeneic HCT for a hematological malignancy between 2016 and 2020. Of these, 5228 (14%) had obesity (BMI ≥ 30 kg/m2), 1415 (4%) had diabetes (requiring treatment with insulin or oral hypoglycemics), and 688 (2%) had obesity + diabetes pre-transplantation. Compared with patients without diabetes or obesity, the hazard ratio (HR) of grade II-IV acute GvHD was 1.00 (95% confidence interval [CI] 0.94-1.06, p = 0.89) for patients with obesity, 0.95 (CI 0.85-1.07, p = 0.43) for patients with diabetes, and 0.96 (CI 0.82-1.13, p = 0.63) for patients with obesity + diabetes. Non-relapse mortality was higher in patients with obesity (HR 1.08, CI 1.00-1.17, p = 0.047), diabetes (HR 1.40, CI 1.24-1.57, p < 0.001), and obesity + diabetes (HR 1.38, CI 1.16-1.64, p < 0.001). Overall survival after grade II-IV acute GvHD was lower in patients with diabetes (HR 1.46, CI 1.25-1.70, p < 0.001). Pre-transplantation diabetes and obesity did not influence the risk of developing acute GvHD, but pre-transplantation diabetes was associated with poorer survival after acute GvHD.

U2 - 10.1038/s41409-023-02154-6

DO - 10.1038/s41409-023-02154-6

M3 - SCORING: Journal article

C2 - 38062242

VL - 59

SP - 255

EP - 263

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

ER -